Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- Wall Street closes down sharply after Fed holds rates unchanged
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Pulse Biosciences Quarterly Investor Conference Call
February 7, 2019 4:01 PM ESTFirst patient treated in the CellFX back acne clinical feasibility study
Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel medical therapy company bringing to market its proprietary CellFX System, today reported recent corporate developments, and financial results for the quarter and year-ended December 31, 2018.
The Company also announced today treatment of the first of up to 20 patients in a clinical feasibility study to evaluate the CellFX... More
